MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

obesity overweight weight loss weigh
Biotech

MetaVia weighs in with 9% loss to enter the obesity ring

The biotech reported average weight loss of 9.1% in people who received its dual agonist of GLP-1 and glucagon in a phase 1 trial.
Nick Paul Taylor Jan 5, 2026 10:44am
person throwing away garbage or recycling

After $4.8B Amicus buy, BioMarin drops genetic disease asset

Dec 22, 2025 11:12am
next step ladder climb succeed win

Altimmune eyes phase 3 MASH trial as weight loss deepens

Dec 19, 2025 8:30am
liver

FDA qualifies 1st AI drug development tool in MASH

Dec 9, 2025 12:12pm
ESMO AstraZeneca

AstraZeneca drops MASH drug over disappointing data

Nov 6, 2025 5:21am
Novo Nordisk

Novo drops oncology ambitions, early-stage MASH prospects

Nov 5, 2025 7:21am